Tocilizumab
Actemra, RoActemra (tocilizumab) is an antibody pharmaceutical. Tocilizumab was first approved as Actemra on 2009-01-15. It is used to treat giant cell arteritis, juvenile arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat juvenile arthritis and rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.
| Trade Name | RoActemra |
|---|---|
| Common Name | Tocilizumab |
| ChEMBL ID | CHEMBL1237022 |
| Indication | giant cell arteritis, juvenile arthritis, rheumatoid arthritis |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
